Evidence map›Paper›PMID 31165042›Full record

ArticleFrontiers in oncology2019

Study of Promoter Methylation Patterns of HOXA2, HOXA5, and HOXA6 and Its Clinicopathological Characteristics in Colorectal Cancer.

Daojiang Li, Yang Bai, Zhicai Feng, Wanwan Li, Chunxing Yang, Yihang Guo, Changwei Lin, Yi Zhang, Quanyong He, Gui Hu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Epigenetics · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Daojiang LiDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yang BaiDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Zhicai FengDepartment of Burns and Plastic Surgery of the Third Xiangya Hospital of Central South University, Changsha, China.
Wanwan LiDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Chunxing YangDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yihang GuoDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Changwei LinDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Yi ZhangDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Quanyong HeDepartment of Burns and Plastic Surgery of the Third Xiangya Hospital of Central South University, Changsha, China.
Gui HuDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Xiaorong LiDepartment of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research on DNA methylation offers great potential for the identification of biomarkers that can be applied for accurately assessing an individual's risk for cancer. In this article, we try to find the ideal epigenetic genes involved in colorectal cancer (CRC) based on a CRC database and our CRC cohort. The top 20 genes with an extremely high frequency of hypermethylation in CRC were identified in the latest database. Remarkably, 3 HOXA genes were included in this list and ranked at the top. The percentage of methylation in the HOXA5, HOXA2, and HOXA6 genes in CRC were up to 67.62, 58.36, and 31.32%, respectively, and ranked first in CRC among all human tumor tissues. Paired colorectal tumor samples and adjacent non-tumor colorectal tissue samples and four CRC cell lines were selected for MethylTarget™ assays. The results demonstrated that CRC tissues and cells had a stronger methylation status around the 3 HOXA gene promoter regions compared with adjacent non-tumor colonic tissue samples. The Receiver operator characteristic curve (ROC) curves for HOXA genes show excellent diagnostic ability in distinguishing tissue from healthy individuals and CRC patients, especially for Stage I patients (AUC = 0.9979 in HOXA2, 0.9309 in HOXA5, and 0.8025 in HOXA6). An association analysis between the methylation pattern of HOXA genes and clinical indicators was performed and found that HOXA2 methylation was significantly associated with age, N, stage, M, lymphovascular invasion, perineural invasion, lymph node number. HOXA5 methylation was associated with age, T, M, stage, and tumor status, and HOXA6 methylation was associated with age and KRAS mutation. Notably, we found that the highest methylation of HOXA5 and HOXA2 occurs in the early stages of colorectal cancer tissues such as stage I, N0, MO, and non-invasive tissues. The methylation levels declined as tumors progressed. However, methylation level at any stage of the tumor was still significantly higher than in normal tissues (

Indexed as

biomarkercolorectal cancerearly stageHOXA2HOXA5HOXA6methylation

Identifiers

PMID31165042
PMCPMC6536611
OpenAlexW2946217638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.